{
  "id": "pfizer",
  "company": "Pfizer",
  "title": "End-to-End AI Integration",
  "summary": "CAIO-led hybrid model with AI/ML Fab Lab, Predictive Analytics Incubator, and PACT partnership reducing drug candidate development from 1+ year to 30 days.",

  "phenotype": "hybrid",
  "phenotypeSubtype": null,

  "diagramTemplate": "hybrid-hub-spoke",
  "architecturalPrinciples": ["locus-of-innovation", "resource-allocation", "stance-on-uncertainty"],
  "designPrinciples": ["ride-the-exponential", "rapid-iteration-cycles"],

  "content": {
    "whatItIs": "Pfizer has built a comprehensive AI organization under newly appointed CAIO Berta Rodriguez-Hervas, combining internal capability building (AI/ML Fab Lab, Predictive Analytics Incubator) with strategic partnerships. The PACT (Pfizer-Amazon-Claude Trifecta) partnership represents a new model of pharmaceutical AI deployment.",
    "howItWorks": [
      "CAIO position established to provide executive-level AI leadership and strategy",
      "AI/ML Fab Lab serves as internal experimentation and capability building center",
      "Predictive Analytics Incubator focuses on applied AI for drug discovery",
      "PACT partnership with AWS and Anthropic provides enterprise AI infrastructure",
      "Development cycles reduced from 6+ weeks to 6 weeks through AI acceleration",
      "Drug candidate development compressed from 1+ year to 30 days using AI"
    ],
    "coreInsight": "The 30-day drug candidate development metric represents a 10x+ compression of traditional timelines - demonstrating that AI can fundamentally change the economics and speed of pharmaceutical R&D, not just incrementally improve existing processes.",
    "keyMetrics": "Drug candidate development reduced from 1+ year to 30 days, development cycles cut to 6 weeks, CAIO appointed 2025",
    "sources": ["Industry reports January 2026", "Partnership announcements", "Pfizer investor communications"]
  },

  "lastUpdated": "2026-01-20"
}
